Categories Cancer Risk

Study: Mutations in BRCA1 or BRCA2 may increase risk for endometrial cancer

A Dutch study added further evidence that women with a BRCA1 mutation may have an elevated risk for endometrial cancer. The study found that the endometrial cancer in women with either a BRCA1 or BRCA2 mutation was more likely to be an aggressive form of cancer associated with a poor outcomes. (posted 11/30/21)

Este artículo está disponible en español.

Study: Do sugared beverages increase the risk of early-onset colorectal cancer?

A study of female nurses in the U.S. suggests that a high intake of sugar-sweetened beverages may increase the risk of colorectal cancer before age 50. However, researchers saw few early-onset colorectal cancer cases which limited the findings. (posted 9/21/21)

Este artículo está disponible en español.

Article: Transgender peoples' perspectives of being diagnosed with gender-associated cancer

An ABC News article provides viewpoints and data that conveys the added stress experienced by transgender and gender-nonconforming people when they are diagnosed with gender-associated cancer (e.g., ovarian or prostate cancer) that does not match their gender identity. (posted 9/13/21)

Este artículo está disponible en español.

Study: Cancer risks of people with inherited PALB2 mutations

In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)

Este artículo está disponible en español.

Study: Birth control pills may offer long-term protection against endometrial and ovarian cancer

A large study showed that birth control pills may protect against endometrial and ovarian cancers, even years after use was discontinued. (posted 6/1/21)

Este artículo está disponible en español.

Study: Daily high-dose aspirin taken for at least 2 years reduces the risk of colorectal cancer but not other cancers in people with Lynch syndrome

Research has shown that daily aspirin use can reduce the risk of colon and other cancers. The Cancer Prevention Program 2 (CaPP2) study looked at the effect of daily aspirin in patients with Lynch syndrome. After 10 years of follow-up, the results showed that taking daily aspirin for two years reduced the frequency of colon cancer in patients with Lynch syndrome, and importantly, did not result in an increase in side-effects or complications. No benefit was seen for other Lynch syndrome-related cancers, including endometrial cancer. (5/17/21)

Este artículo está disponible en español.

Update: Cancer disparities: Colorectal cancer in African Americans

The American Association for Cancer Research (AACR) released a 2020 report about cancer disparities among racial and ethnic groups in the United States. In this XRAY review, we highlight data from the report about the burden of colorectal cancer in African Americans, who have the highest rates of diagnosis and death related to the disease among all racial and ethnic groups. (Posted 4/27/21)

Este artículo está disponible en español.

Study: Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer

This study looked at the impact of daily aspirin use on the risk for many types of cancers and whether this effect can be modified by risk factors such as obesity, smoking, physical inactivity or a family history of cancer. Daily aspirin use: 

• lowered the risk for colorectal cancer, but this effect was lost as Body Mass Index (BMI) increased.
• lowered the risk of ovarian cancer risk among obese women.
• offered little or no protection against breast, endometrial or advanced prostate cancer.

(posted 3/19/21)

Este artículo está disponible en español.

Study: Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations

Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)

Este artículo está disponible en español.

Update: FDA approves new imaging drug for detecting spread of prostate cancer

On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)

THIS INFORMATION HAS BEEN UPDATED on 5/10/2022:  On March 23, 2022 the U.S. Food and Drug Administration (FDA) approved a new drug called Pluvicto to treat patients with metastatic castration-resistant prostate cancer. ON the same day, the FDA also approved a new imaging drug called Locametz (a brand of Gallium 68 PSMA-11) for identification of those patients who would benefit from treatment with Pluvicto. Read about the FDA approval of Pluvicto and Locametz here.

Este artículo está disponible en español.